Escalon Medical Corp
ESMC
ESMC was delisted on the 17th of November, 2016.
1 hedge funds and large institutions have $1K invested in Escalon Medical Corp in 2017 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
67% less funds holding
Funds holding: 3 → 1 (-2)
95% less capital invested
Capital invested by funds: $22K → $1K (-$21K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WS
Wedbush Securities
Los Angeles,
California
|
-$19K |
| 2 |
California Public Employees Retirement System
Sacramento,
California
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PAM
1
Panagora Asset Management
Boston,
Massachusetts
| $1K | – | – | – |
|
|
WS
2
Wedbush Securities
Los Angeles,
California
| – | -$19K | -181,183 | Closed |
|
|
3
California Public Employees Retirement System
Sacramento,
California
| – | -$2K | -17,100 | Closed |
|
ESMC Hedge Fund Activity: Q1 2017 in Review
1 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Escalon Medical Corp (ESMC) for Q1 2017, worth a combined $1K — down 95% from $22K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ESMC and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Wedbush Securities, exiting entirely with an estimated $19K sold.
- 1 institutional investor held Escalon Medical Corp (ESMC) as of Q1 2017, down from 3 in Q4 2016.
- Funds reported $1K of Escalon Medical Corp stock for Q1 2017, down 95% quarter-over-quarter.
- 0 funds opened new Escalon Medical Corp positions in Q1 2017 and 2 closed out, a net change of -2 holders.
- The largest Escalon Medical Corp seller in Q1 2017 was Wedbush Securities, an estimated $19K sold.
Based on aggregated 13F filings for Q1 2017.